News coverage about Mirati Therapeutics (NASDAQ:MRTX) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mirati Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.20471837273 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

NASDAQ MRTX opened at $58.60 on Friday. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -21.08 and a beta of 2.04. Mirati Therapeutics has a one year low of $4.75 and a one year high of $65.35.

Mirati Therapeutics (NASDAQ:MRTX) last posted its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.16). equities research analysts expect that Mirati Therapeutics will post -2.88 earnings per share for the current fiscal year.

Several research analysts recently commented on the stock. Cann raised their price target on shares of Mirati Therapeutics from $35.00 to $62.00 and gave the stock an “average” rating in a research note on Monday, July 9th. ValuEngine raised shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. HC Wainwright raised their target price on shares of Mirati Therapeutics to $63.00 and gave the company a “buy” rating in a research report on Friday, July 20th. Zacks Investment Research downgraded shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. Finally, BidaskClub raised shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $47.75.

In other news, SVP Jamie Christensen sold 10,207 shares of the firm’s stock in a transaction dated Wednesday, June 27th. The shares were sold at an average price of $49.15, for a total value of $501,674.05. Following the sale, the senior vice president now directly owns 8,085 shares in the company, valued at approximately $397,377.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Charles M. Baum sold 51,810 shares of the firm’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $57.55, for a total transaction of $2,981,665.50. Following the completion of the sale, the chief executive officer now owns 102,742 shares in the company, valued at $5,912,802.10. The disclosure for this sale can be found here. Company insiders own 4.86% of the company’s stock.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.

See Also: Book Value Per Share in Stock Trading

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.